Human Tissue Authority licence application

ABZENA PLC

("Abzena", the "Company" or the "Group")

Update on Human Tissue Authority licence application

6 February 2015

Cambridge, UK - Abzena plc (AIM: ABZA) ("Abzena"), a revenue-generating life sciences group providing services and technologies that enable the development of better biopharmaceutical products, announces that the Human Tissue Authority has confirmed that a licence will be granted for the storage of blood samples for research, as referred to in Abzena's interim statement announced on 12 December 2014. The historical absence of a licence has been referred to the relevant authority for investigation as a potential breach of the Human Tissue Act. This process is not expected to have any material impact on the business.

About Abzena

Abzena provides proprietary technologies and complementary services to enable the development of better biopharmaceuticals. The Group comprises PolyTherics and Antitope which have established a broad suite of services and technologies that are designed to improve the chances of successful development of antibodies and proteins with enhanced therapeutic benefits.

Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.

PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimization of the therapeutic properties of biopharmaceuticals.

The Group has built a global customer base over the past decade which includes the majority of the top 20 biopharmaceutical companies, many large and small biotech companies, and academic groups.

Abzena is quoted on the AIM market of the London Stock Exchange under the symbol ABZA.

www.abzena.com 

For more information, please contact:

John Burt (Chief Executive Officer)

Julian Smith (Chief Financial Officer)

Abzena plc

Tel: +44 (0)1223 903498

Email: [email protected] or [email protected]

Christopher Golden and Bobbie Hilliam

Cenkos Securities (Nominated Adviser and Broker)

Tel: +44 (0)20 7397 8900

Mark Swallow or Chris Gardner

Citigate Dewe Rogerson (Corporate and Financial PR)

Tel: +44 (0)20 7638 9571

Email: [email protected]